Description: DongKoo Bio&Pharma. Co., Ltd. engages in the research, development, manufacture, and sale of medicines in South Korea. The company offers prescribed medicines, such as digestants, other analgesics and antipyretics, nonsteroidal anti-inflammatory drugs, oral hypoglycemic agents, antiplatelet agents, nootropics and neurotonics, H+ pump inhibitors, antihistamines and antiallergics, and decongestants and nasal sprays, as well as non-selective a, ß-blockers. It also provides non-medical products, medical apparatus, and other cosmetic products, as well as household items and health functional foods. In addition, the company offers contract manufacturing services for OEMs and ODMs in the areas of prescribed medicine, general medicine, health foods, general foods, and quasi-authorized drugs in the form of soft gelatin capsules, hard capsules, tablets, powders, granules, externals, and liquids. DongKoo Bio&Pharma. Co., Ltd. has a partnership with Cerbios-pharma for the development of Cenilton for prostate treatment; and Ventrux for active probiotic intestinal treatment, as well as has a partnership with Lion Pharmaceutical company for the development of Dentheth ointment for the treatment of gum disease. The company exports its products to Vietnam, New Zealand, Thailand, Hong Kong, and Singapore. DongKoo Bio&Pharma. Co., Ltd. was founded in 1970 and is based in Seoul, South Korea.
Home Page: www.dongkoo.com
M State Building
Seoul,
05836
South Korea
Phone:
82 2 2684 5421
Officers
| Name | Title |
|---|---|
| Mr. Cho Yong-Joon | Pres |
Exchange: KQ
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0.737 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |